466 related articles for article (PubMed ID: 35072589)
1. Treating opioid use disorder with rapid micro induction technique of sublingual buprenorphine/naloxone in an outpatient setting-a case report.
Martell JP; Konakanchi JS; Sethi R
J Addict Dis; 2022; 40(3):439-443. PubMed ID: 35072589
[TBL] [Abstract][Full Text] [Related]
2. Assessing perceptions about medications for opioid use disorder and Naloxone on Twitter.
Tofighi B; El Shahawy O; Segoshi A; Moreno KP; Badiei B; Sarker A; Krawczyk N
J Addict Dis; 2021; 39(1):37-45. PubMed ID: 32835641
[No Abstract] [Full Text] [Related]
3. Developing A Rapid Transfer from Opioid Full Agonist to Buprenorphine: "Ultrarapid Micro-Dosing" Proof of Concept.
Azar P; Mathew N; Mahal D; Wong JSH; Westenberg JN; Schütz CG; Greenwald MK
J Psychoactive Drugs; 2023; 55(1):94-101. PubMed ID: 35152847
[TBL] [Abstract][Full Text] [Related]
4. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.
Morgan JR; Schackman BR; Leff JA; Linas BP; Walley AY
J Subst Abuse Treat; 2018 Feb; 85():90-96. PubMed ID: 28733097
[TBL] [Abstract][Full Text] [Related]
5. Low Dose Buprenorphine Induction With Full Agonist Overlap in Hospitalized Patients With Opioid Use Disorder: A Retrospective Cohort Study.
Bhatraju EP; Klein JW; Hall AN; Chen DR; Iles-Shih M; Tsui JI; Merrill JO
J Addict Med; 2022 Jul-Aug 01; 16(4):461-465. PubMed ID: 34954743
[TBL] [Abstract][Full Text] [Related]
6. Safety and preliminary outcomes of short-acting opioid agonist treatment (sOAT) for hospitalized patients with opioid use disorder.
Thakrar AP; Uritsky TJ; Christopher C; Winston A; Ronning K; Sigueza AL; Caputo A; McFadden R; Olenik JM; Perrone J; Delgado MK; Lowenstein M; Compton P
Addict Sci Clin Pract; 2023 Feb; 18(1):13. PubMed ID: 36829242
[TBL] [Abstract][Full Text] [Related]
7. Buprenorphine/naloxone versus methadone and lofexidine in community stabilisation and detoxification: A randomised controlled trial of low dose short-term opiate-dependent individuals.
Law FD; Diaper AM; Melichar JK; Coulton S; Nutt DJ; Myles JS
J Psychopharmacol; 2017 Aug; 31(8):1046-1055. PubMed ID: 28631527
[TBL] [Abstract][Full Text] [Related]
8. A Case Report: Rapid Micro-Induction of Buprenorphine/Naloxone to Administer Buprenorphine Extended-Release in an Adolescent With Severe Opioid Use Disorder.
Azar P; Wong JSH; Jassemi S; Moore E; Vo DX; Nikoo M; Young S
Am J Addict; 2020 Nov; 29(6):531-535. PubMed ID: 32346944
[TBL] [Abstract][Full Text] [Related]
9. A Descriptive analysis of urine drug screen results in patients with opioid use disorder managed in a primary care setting.
Sobel HG; Warrington JS; Francis-Fath S; Crocker AM; Berger CA
Addict Sci Clin Pract; 2021 Sep; 16(1):59. PubMed ID: 34593036
[TBL] [Abstract][Full Text] [Related]
10. Extended-Release Injection vs Sublingual Buprenorphine for Opioid Use Disorder With Fentanyl Use: A Post Hoc Analysis of a Randomized Clinical Trial.
Nunes EV; Comer SD; Lofwall MR; Walsh SL; Peterson S; Tiberg F; Hjelmstrom P; Budilovsky-Kelley NR
JAMA Netw Open; 2024 Jun; 7(6):e2417377. PubMed ID: 38916892
[TBL] [Abstract][Full Text] [Related]
11. Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial.
Jutras-Aswad D; Le Foll B; Ahamad K; Lim R; Bruneau J; Fischer B; Rehm J; Wild TC; Wood E; Brissette S; Gagnon L; Fikowski J; Ledjiar O; Masse B; Socias ME;
Am J Psychiatry; 2022 Oct; 179(10):726-739. PubMed ID: 35702828
[TBL] [Abstract][Full Text] [Related]
12. Successful Buprenorphine/Naloxone Low-dose Induction in Pregnancy: A Case Report.
Coish R; Hardial J
J Addict Med; 2023 Jan-Feb 01; 17(1):114-116. PubMed ID: 35916416
[TBL] [Abstract][Full Text] [Related]
13. 48-hour Induction of Transdermal Buprenorphine to Sublingual Buprenorphine/Naloxone: The IPPAS Method.
Azar P; Wong JSH; Mathew N; Vogel M; Perrone J; Herring AA; Krausz RM; Montaner JSG; Greenwald MK; Maharaj AR
J Addict Med; 2023 Mar-Apr 01; 17(2):233-236. PubMed ID: 36149002
[TBL] [Abstract][Full Text] [Related]
14. Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 "optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)".
Shulman M; Weiss R; Rotrosen J; Novo P; Costello E; Nunes EV
Addict Sci Clin Pract; 2021 Mar; 16(1):15. PubMed ID: 33676577
[TBL] [Abstract][Full Text] [Related]
15. Commentary on Hser et al. (2014): to retain or not to retain-open questions in opioid maintenance therapy.
Soyka M; Hillemacher T
Addiction; 2014 Jan; 109(1):88-9. PubMed ID: 24438113
[No Abstract] [Full Text] [Related]
16. Rapid Transition From Methadone to Buprenorphine Utilizing a Micro-dosing Protocol in the Outpatient Veteran Affairs Setting.
De Aquino JP; Fairgrieve C; Klaire S; Garcia-Vassallo G
J Addict Med; 2020; 14(5):e271-e273. PubMed ID: 32011408
[TBL] [Abstract][Full Text] [Related]
17. Flexible Buprenorphine/Naloxone Treatment Models: Safe and Effective in Reducing Opioid Use Among Persons With Prescription Opioid Use Disorder.
Saunders EC
Am J Psychiatry; 2022 Oct; 179(10):699-701. PubMed ID: 36181331
[No Abstract] [Full Text] [Related]
18. Management of opioid withdrawal and initiation of medications for opioid use disorder in the hospital setting.
Carswell N; Angermaier G; Castaneda C; Delgado F
Hosp Pract (1995); 2022 Oct; 50(4):251-258. PubMed ID: 35837678
[TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up assessment of opioid use outcomes among individuals with comorbid mental disorders and opioid use disorder treated with buprenorphine or methadone in a randomized clinical trial.
Hser YI; Zhu Y; Fei Z; Mooney LJ; Evans EA; Kelleghan A; Matthews A; Yoo C; Saxon AJ
Addiction; 2022 Jan; 117(1):151-161. PubMed ID: 34105213
[TBL] [Abstract][Full Text] [Related]
20. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
Hser YI; Saxon AJ; Huang D; Hasson A; Thomas C; Hillhouse M; Jacobs P; Teruya C; McLaughlin P; Wiest K; Cohen A; Ling W
Addiction; 2014 Jan; 109(1):79-87. PubMed ID: 23961726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
